CDK9-IN-45

CDK9-IN-45 (Compound B11) is a highly selective CDK9 inhibitor with IC50 values for CDK9 and CDK1 of 7.13 and 489.5 nM respectively. CDK9-IN-45 exhibits a potent inhibitory effect on colorectal cancer cells. CDK9-IN-45 induces cell apoptosis and leads to significant accumulation of ROS. CDK9-IN-45 activates Caspase-3, downregulates Mcl-1, XIAP, and c-Myc. CDK9-IN-45 can be used for research on colorectal cancer[1].

Product Specifications

Target

Apoptosis; Bcl-2 Family; Caspase; CDK; c-Myc; IAP; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer

Smiles

FC1=CC=C(C2=CC=NC(NC3=CC(NN=C4C(N5CC6(COC6)C5)=O)=C4C=C3)=C2)C(OC)=C1

Molecular Formula

C25H22FN5O3

Molecular Weight

459.47

References & Citations

[1]Sun X, et al. Design, synthesis, and activity evaluation of selective CDK9 inhibitors containing indazole fragments. Bioorg Chem. 2025 Oct 13;166:109083.